MoonLake Immunotherapeutics (NASDAQ: MLTX)

For #media #investors:   Our Medical Affairs team members Eva Cullen PhD, Naomi Attar and Sónia Guerra Gomes are attending IFPA’s 7th World Psoriasis & Psoriatic Arthritis Conference this week in Stockholm. MoonLake clinical trial data is set to be a highlight of the conference — with our abstract one of only six submissions selected by the IFPA scientific committee for an oral presentation. The presentation will report Week 12 multidomain outcomes in the PsA ARGO trial, with Prof. Joseph F Merola MD MMSc (Chair, Dermatology and Professor, Dermatology, Medicine & Rheumatology; UT Southwestern Medical Center, Dallas, TX, USA) as the presenting author. Morning plenary session, June 28, 2024 Main Auditorium, Stockholm Waterfront Congress Center We hope to see you there!   If you are interested in arranging a meeting, please contact us at info@moonlaketx.com.   #MoonLake #MLTX #PsA

  For #media #investors:   We were thrilled to win Best Communication Award at the European Mediscience Awards 2024!   This achievement would not have been possible without the support, encouragement, and inspiration from the incredible network of the MoonLake Communications Team! It’s also a testament to the power of teamwork and effective communication!   Please find below our CFO, Matthias Bodenstedt with Patrícia Marques de Sousa, our Director of Corporate Affairs accompanied by Mary-Jane Elliott, Managing Partner, ICR Consilium, Nina Hossain and Michael White, Head of Life Sciences and Healthcare, HSBC Innovation Banking.   Congratulations to all the other award winners and nominees! #MLTX #MoonLake #nanobody #HS #PsA #IL17A #IL17F

For #media #investors:   Our CFO Matthias Bodenstedt is attending the Stifel Europe Healthcare Summit taking place in Lyon on 25-27 June. Contact us at ir@moonlaketx.com if you are interested in meeting.   #MoonLake #MLTX #IL17A #IL17F #HS #PsA #nanobody

For #media #investors:   Thank you EULAR - European Alliance of Associations for Rheumatology Congress for another engaging meeting! We thoroughly enjoyed hearing about the latest advances in #rheumatology and discussing these with some of the brightest minds in the field.   Here are some photos of our team in action and Prof Iain B. McInnes, Vice-Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow, presenting key Week 12 efficacy and safety outcomes from the ARGO trial.   #MoonLake #MLTX #PsA #HS #IL17F #IL17A

For #media #investors:   Our Co-founder and CSO Prof. Dr. Kristian Reich along with our medical affairs team, including Senior Director Global Medical Affairs Eva Cullen PhD, Naomi Attar, Sara Souto Pereira and Sónia Guerra Gomes will be attending the EULAR - European Alliance of Associations for Rheumatology Congress 2024 in Vienna, Austria this week.   The congress marks a watershed moment for MoonLake with the rheumatology community, as our PsA trial data will be presented to a clinical audience for the first time — Prof Iain B. McInnes, Vice-Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow, will present key Week 12 efficacy and safety outcomes from the ARGO trial in the ‘SpA & PsA – Treatment effects and response prediction’ clinical abstract session.   Session date and time: Thursday 13th June 10:30 – 12:00 Session room: A2 Expected presentation time: 11:40 -11:50   We hope to see you there!   If you are interested in arranging a meeting, please contact us at info@moonlaketx.com.   #MoonLake #MLTX #PsA #Congress #Vienna  

For #media #investors: Today we announced that MoonLake received positive regulatory feedback from both the FDA and EMA on our Phase 3 program for our Nanobody® in psoriatic arthritis (PsA). This new builds upon the positive regulatory feedback for our Phase 3 VELA program in hidradenitis suppurativa (HS). The new PsA program, named IZAR, will comprise two trials which are anticipated to start in Q4 2024 with primary endpoint readout by the end of 2026.   Please read more here: https://lnkd.in/dHzpgjjG #MLTX #MoonLake #Immunotherapeutics #psoriasis #nanobody #IL17F #IL17A #HS #PsA #dermatology

LinkedIn:   For #media #investors:   Our CEO, Jorge Santos da Silva, CFO, Matthias Bodenstedt and Director of IR and BD, Carla Bretes will be attending the Goldman Sachs 45th Annual Global Healthcare Conference taking place from June 10th –13th. Jorge and Matthias will be hosting a fireside chat along on MoonLake’s recent milestones, initiation of Phase 3 trials for HS and its next steps.   Contact us at ir@moonlaketx.com if you are interested in meeting.   #MoonLake #Nanobodies #MLTX #nanobody #IL17F #IL17A #HS #PsA 

For #Media #Investors   As part of #HSAwarenessWeek, we want to provide an update on our ambition to elevate outcomes for people who suffer from this debilitating disease. Last month, we screened our first patients in our global Phase 3 clinical program for patients with moderate-to-severe hidradenitis suppurativa. This milestone marks a significant step forward in our goal to develop treatments for those in need. Additionally, we will start another Phase 3 program focused on adolescent HS. HS may often begin in the teenage years, yet limited treatment options are available for adolescents, despite the need for timely intervention in a disease such as HS that leads to irreversible tissue damage. By addressing the needs of all HS patients, regardless of age, we hope to advance innovative treatments and improving the quality of life for everyone who is affected by this challenging condition.   #HS #MLTX #IL17A #IL17F #IL17 #PsA

For #Media #investors As part of our mission to treat #HS, MoonLake is proud to be a Diamond Partner with the non-profit organisation Hidradenitis Suppurativa Foundation, Inc. Like us, they are committed to improving the lives of people affected by HS and run numerous advocacy, education, and research initiatives to increase public awareness for this underdiagnosed disease. In addition to helping fund their important work, our partnership enables us to work closely with HS community to make sure that their needs are addressed as we continue to develop our therapeutic Nanobody®, which is in Phase 3 clinical development. To learn more about HS, visit our page here: https://lnkd.in/g7E2vQnQ   #MoonLake #HS #MLTX #IL17A #IL17F #IL17 #PsA

For #media #investors: This week marks the start of #HSAwarenessWeek 2024, dedicated to shedding light on hidradenitis suppurativa (HS), a severely debilitating chronic skin disease that can result in irreversible tissue destruction and scarring. HS may often begin in the teenage years and can have a profound negative impact on quality of life, with higher morbidity than many other dermatological conditions. We are proud to be supporting the HS community in raising awareness of this devastating condition. Early diagnosis is crucial to prevent the worsening of symptoms and irreversible tissue damage. To learn more about HS, visit our page here: https://lnkd.in/g7E2vQnQ #MLTX #MoonLake #nanobody #HS #IL-17A #IL-17F